PUBLISHER: DelveInsight | PRODUCT CODE: 1226622
PUBLISHER: DelveInsight | PRODUCT CODE: 1226622
"LYNPARZA Drug Insight and Market Forecast - 2032" report provides comprehensive insights about LYNPARZA for ER +ve HER2-ve Breast Cancer in the United States. A detailed picture of the LYNPARZA for ER+ve HER2-ve Breast Cancer in the United States for the study period 2019-2032 is provided in this report along with a detailed description of the LYNPARZA for ER+ve HER2-ve Breast Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LYNPARZA market forecast, analysis for ER+ve HER2-ve Breast Cancer in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in ER+ve HER2-ve Breast Cancer.
LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor, including PARP1, PARP2, and PARP3. It is used in patients with deleterious or suspected deleterious gBRCAm, HR+ HER2- metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with HR+ breast cancer can also be treated with prior endocrine therapy or be considered inappropriate for endocrine therapy. This drug is also used as a first-line maintenance treatment of BRCA-mutated advanced ovarian cancer. LYNPARZA (Olaparib) is now indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm HER2- high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients will be selected for treatment based on an FDA-approved companion diagnostic test for LYNPARZA (Olaparib).
Dosage and Administration
Mechanism of Action
LYNPARZA is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes. PARP enzymes are involved in normal cellular functions such as DNA transcription and DNA repair. Olaparib has been shown to inhibit the growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer, both as monotherapy and following platinum-based chemotherapy.
Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA and non-BRCA proteins involved in the homologous recombination repair (HRR) of DNA damage and correlated with the platinum response. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increase the formation of PARP-DNA complexes, resulting in DNA damage and cancer cell death.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
LYNPARZA Analytical Perspective by DelveInsight
This report provides a detailed market assessment of LYNPARZA in ER+ve HER2-ve Breast Cancer in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of LYNPARZA in ER+ve HER2-ve Breast Cancer covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions